Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022

Rhea-AI Summary

Cybin Inc. (AMEX:CYBN) will report its third-quarter financial results for the period ending December 31, 2021, on February 10, 2022. A conference call will take place at 8:30 a.m. (EST) on the same day, featuring CEO Doug Drysdale and the management team, who will discuss the results and answer questions. Cybin is focused on developing safe and effective therapeutics for mental health issues, leveraging partnerships with leading scientists and proprietary drug discovery platforms. Investors can access a webcast of the call.

Positive

• Focus on developing innovative therapeutics for mental health issues.
• Strong partnership with world-class scientists enhances research credibility.

Negative

• None.

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” today announced that it will report financial results for its third quarter ended December 31, 2021 on Thursday, February 10, 2022.

A conference call will be held on the same day at 8:30 a.m. (EST) to discuss the results and recent business updates. The call will be hosted by Doug Drysdale, Cybin’s Chief Executive Officer. Mr. Drysdale and other members of the management team will be available to answer questions from participants following the prepared remarks.

CONFERENCE CALL DETAILS:

DATE:		Thursday, February 10, 2022
TIME:		8:30 a.m. (EST)
DIAL-IN		1-844-200-6205 (U.S. toll free) or 1-833-950-0062 (Canada toll free)
CODE		868712
WEBCAST		https://events.q4inc.com/attendee/296855699

An archived webcast will also be available on the Company’s Investor Relations site under the Events & Presentations page.

About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005364/en/

Investors & Media:

Leah Gibson

Vice President, Investor Relations

Cybin Inc.

leah@cybin.com

Source: Cybin Inc.

FAQ

When will Cybin report its third-quarter financial results?

Cybin will report its third-quarter financial results on February 10, 2022.

What time is the Cybin conference call scheduled?

The conference call is scheduled for 8:30 a.m. (EST) on February 10, 2022.

Who will host the conference call for Cybin's financial results?

The conference call will be hosted by Doug Drysdale, Cybin's CEO.

What is Cybin's focus as a biopharmaceutical company?

Cybin focuses on developing therapeutics for mental health issues using psychedelics.

How can investors access the Cybin conference call?

Investors can access the conference call via a webcast link provided in the press release.